ArticleAntimicrobial agents and chemotherapy2000
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens.
Article in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 80 citations in OpenAlex.
- Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.Antimicrobial agents and chemotherapy · 2007Trial
- Real-world correlation between therapeutic drug monitoring and clinical outcomes of the antifungal drug posaconazole: a single-center retrospective cohort study.Frontiers in pharmacology · 2025Article
- Rare Invasive Yeast Infections in Greek Neonates and Children, a Retrospective 12-Year Study.Journal of fungi (Basel, Switzerland) · 2020Article
- Antiproliferative and Antimicrobial Activities of Secondary Metabolites and Phylogenetic Study of EndophyticFrontiers in microbiology · 2018Article
- Synthesis and biological evaluation of hydrazone derivatives as antifungal agents.Molecules (Basel, Switzerland) · 2015Article
- Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.Antimicrobial agents and chemotherapy · 2008Article
- 3-Benzyl-sulfanyl-5-(4-phenyl-1H-1,2,3-triazol-1-ylmeth-yl)-4H-1,2,4-triazol-4-amine.Acta crystallographica. Section E, Structure reports online · 2008Article
- In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.Antimicrobial agents and chemotherapy · 2006Article
- Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.Antimicrobial agents and chemotherapy · 2006Article
- In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.Antimicrobial agents and chemotherapy · 2005Article
- Activities of available and investigational antifungal agents against rhodotorula species.Journal of clinical microbiology · 2005Article
- Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates.Journal of clinical microbiology · 2003Article
- In vitro activity of posaconazole against clinical isolates of dermatophytes.Journal of clinical microbiology · 2001Article
- Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.Journal of clinical microbiology · 2001Article
- In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.Antimicrobial agents and chemotherapy · 2001Article
- Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.Antimicrobial agents and chemotherapy · 2001Article
- Interactions between triazoles and amphotericin B against Cryptococcus neoformans.Antimicrobial agents and chemotherapy · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A broth microdilution method performed in accordance with the National Committee for Clinical Laboratory Standards guidelines was used to compare the in vitro activity of the new antifungal triazole SCH 56592 (SCH) to that of fluconazole (FLC), itraconazole (ITC), and ketoconazole (KETO) against 257 clinical yeast isolates. They included 220 isolates belonging to 12 different species of Candida, 15 isolates each of Cryptococcus neoformans and Saccharomyces cerevisiae, and seven isolates of Rhodotorula rubra. The MICs of SCH at which 50% (MIC(50)) and 90% (MIC(90)) of the isolates were inhibited were 0.06 and 2.0 microg/ml, respectively. In general, SCH was considerably more active than FLC (MIC(50) and MIC(90) of 1.0 and 64 microg/ml, respectively) and slightly more active than either ITC (MIC(50) and MIC(90) of 0.25 and 2.0 microg/ml, respectively) and KETO (MIC(50) and MIC(90) of 0.125 and 4.0 microg/ml, respectively). Our in vitro data suggest that SCH has significant potential for clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.